Novel Combinations of Human Immunomodulatory mAbs Lacking Cardiotoxic Effects for Therapy of TNBC

SIMPLE SUMMARY: Immunotherapy has revolutionized the management of cancer by improving outcomes of triple-negative breast cancer (TNBC). Recently, programmed death-ligand 1 (PD-L1), was identified as a target for TNBC and several preclinical and clinical trials are currently focusing on combinatoria...

Descripción completa

Detalles Bibliográficos
Autores principales: Vetrei, Cinzia, Passariello, Margherita, Froechlich, Guendalina, Rapuano Lembo, Rosa, Sasso, Emanuele, Zambrano, Nicola, De Lorenzo, Claudia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750931/
https://www.ncbi.nlm.nih.gov/pubmed/35008285
http://dx.doi.org/10.3390/cancers14010121

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750931/
https://www.ncbi.nlm.nih.gov/pubmed/35008285
http://dx.doi.org/10.3390/cancers14010121

Ejemplares similares